Abstract
probenecid but did not reach statistical significance (18 2.6% vs. 22 3.7%, p1⁄40.19, Figure 1A). The most pronounced improvement was in the grade of sperm motility. Rapid linear motility increased significantly after 4 weeks of treatment (5.0 1.3% vs. 16 3.2%, p < 0.005, Figure 1B), and continued after the cessation of treatment (5.0 1.3% vs. 15 8.3%, p < 0.005, Figure 1B). Sperm concentrations remained normal throughout the course of the study. The medication was well-tolerated by all patients. CONCLUSIONS: This is the first study to report improved sperm motility from an oral medication in men with spinal cord injury. Planned placebo-controlled trials will determine optimal dosage regimens. Probenecid holds promise as a simple, effective therapy for low sperm motility in this severely affected group of patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
